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A B S T R A C T
The first aim of the study was to determine the survival rate of the patients with Carcinoma of the Unknown Primary
(CUP) in relation to lymph node status and eventual later identification of the primary tumor. To second one was to in-
vestigate the impact of PET-CT on identification of the primary tumor. We studied 97 patients sent to our University Med-
ical Center with diagnosis of metastasis of unknown primary tumor between 1.1.1997 and 1.9.2009. All patients had
panendoscopy and some had PET-CT at later period. All susceptible patients had a surgery and postoperative radiation
therapy. After the completed their treatment they were followed up at ENT department. With preoperative examinations
we discovered 48 primary tumors. Only in one case of 13 the PET-CT detected the primary tumor not confirmed with
other examination methods. After the treatment we found primary tumors in 10 patients. In 39 patients we didn’t dis-
cover any primary tumor. The 2-year overall survival for 10 patients with found tumor was 80.0%, the 2-year overall sur-
vival for the 39 patients without discovered tumor was 73.8%. The 2-year disease-specific survival for 10 patients with
found tumor was 90.0%, the 2-year disease-specific survival for 39 patients without discovered tumor was 81.6%. The
2-year overall survival for high neck level lymph node metastasis group (N=36) was 80.1%, the 2-year overall survival
for low neck level lymph node group (N=13) was 61.5%. PET-CT method was not particularly useful in detecting pri-
mary tumors in patients with metastasis with unknown primary. Patients with high neck level lymph node metastasis
had statistically significant better survival.
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Introduction
Squamos cell carcinoma has, besides its aggressive lo-
cal growth, a specific quite predictable metastasisp pat-
tern to the regional lymph nodes. Especially interesting
cases are those with patients with metastasis in the neck
lymph nodes, in which we cannot find the primary tumor,
even with the most accurate clinical examination and the
usage of flexible and rigid endoscopes. According to the
data from the literature the incidence of patients with
unknown primary tumor varies tremendously and ac-
counts to as low as 2% to as high as 15%1–5. The reason
for such a big difference in undiscovered primary tumors
is in the different protocols and follow up of the patients
used in different institutions. Another important factor
is whether we limit ourselves to only the squamos cell
carcinoma or also on the other types of cancer (undiffer-
entiated, adenocarcinoma). The definition of the carci-
noma of the unknown primary tumor (CUP) has changed
throughout the time; in the early 70s the diagnosis of the
CUP had been made in cases where the primary tumor
hadn’t been found at the autopsy as well. Nowadays the
diagnosis of the CUP can only be made after the primary
tumor is not found after the accurate patient’s history,
clinical exam, ultrasound, X-ray, endoscopic examination
and biochemical blood workup. In some rare cases a pri-
mary tumor is found a after the treatment of the metas-
tasis.
As there are different protocols of the examinations in
the cytologically confirmed metastasis in the neck lymph
nodes, there are also different approaches to the treat-
ment.
In this article the diagnostic protocol and the treat-
ment of these patients is shown as done in the Depart-
ment of Otorhynolaringology and Maxilofacial Surgery
in the UMC Maribor.
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Patients and Methods
We have performed a retrospective analysis of the pa-
tients diagnosed with the CUP (confirmed with fine nee-
dle biopsy), who were admitted to the department be-
tween January 1st 1997 and June 1st 2011. The survival
analysis was performed for patients admitted until Sept.
1st 2009 for having minimal 2 year follow up.
All patients had endoscopic examination of the upper
aerodigestive system (panendoscopy) either in local or in
general anesthesia. The endoscopic exam included: ex-
amination of the larynx and pharynx with rigid or flexi-
ble telescopes, flexible bronchoscopy and rigid esophago-
scopy. All suspicious lesions were biopsied and ipsilateral
tonsillectomy was performed together with curettage of
the nasopharynx. After 2008 most of the patients had
had a PET/CT prior to panendoscopy. PET/CT was per-
formed in other institution. All sites showing increased
uptake of the 19F deoxyglucose were also biopsied.
In patients were the primary tumor was not found we
performed ipsilateral comprehensive neck dissection.
Postoperatively patients were irradiated under an un-
known primary protocol, encompassing upper aerodiges-
tive tract (from nasopharynx to hypopharynx) if primary
tumor was not found with boost to the region with me-
tastasis. Patients were irradiated 5 days a week in 2 Gy
fractions with tumor dose 60 Gy. Radiotherapy was per-
formed at the Institute of Oncology in Ljubljana. After
the treatment we followed the patients on a regular ba-
sis. For the first year the follow up visits were scheduled
every 2 months and from the second year on, the time in
months between visits corresponded the years passed
since the start of the treatment (e.g. if 4 years have
passed since the start of the treatment, the examination
was done every 4th month). Follow up included an accu-
rate physical exam with the help of flexible endoscopes,
Chest X ray (once a year). Ancillary tests were performed
depending on clinical presentation (e.g. CT scan, MR...)
Patients were divided into two groups: in the first are
patients in whom the primary tumor was never identi-
fied, and in the second are patients in which the primary
tumor was identified after the treatment of the lymph
node metastases during a follow up.
Statistical Methods
All information was collected retrospectively and pro-
cessed with the statistical package MedCalc (Version
11.6., MedCalc Software, Mariakerke, Belgium) at the
Faculty of Medicine, University of Maribor, Slovenia. The
overall survival and disease-specific survival were calcu-
lated using the Kaplan-Meier method6.
The time interval for calculating overall survival was
determined as the time between the date of diagnosis and
the day of death, regardless of the cause of death. For cal-
culating disease-specific survival, the time interval be-
tween the date of diagnosis and the date of death was cal-
culated only if death was considered as being causally
related to the progression of the regional disease.
Results
In the period between 1.1.1997 and 1.9.2009 we man-
aged 96 patients with a cervical lymph node metastasis of
the unknown primary. Twelve of these patients were ex-
cluded from the review. After additional immunocytoche-
mical staining or repeated fine needle biopsy in 6/12 pa-
tients squamous cell carcinoma was not confirmed. Two
patients had metastasis of adenocarcinoma, two metasta-
sis of clear cell carcinoma, one had an extraossal plasmo-
cytoma and one patient had a B cell lymphoma. One fe-
male patient had been previously treated for breast
cancer; another patient was in such poor condition that
no diagnostic workup or specific treatment was possible.
In 3 patients we found suspicious changes in the lungs on
a Chest X ray, which were later confirmed as primary
bronchial carcinoma. In 1 patient we found a cancer of
the nasopharynx with a flexible endoscopy.
In 22/84 patients we identified primary tumor before
or at the beginning of the therapy, in 10 patients the pri-
mary tumor was identified on further examinations after
the treatment for metastases on the neck. Panendoscopy
with one-sided tonsillectomy, curettage of the nasopha-
rynx and biopsy from the suspicious places were done in
all 84 patients. A PET-CT scan was done in 28/84 pa-
tients. According to the protocol the PET-CT should be
done before the panendoscopy, but that was not always
possible, because of the logistic problems. Only 10/28 had
PET/CT scan done before the panendoscopy. PET/CT
scan identified primary tumor in 8 out of 28 patients.
With the panendoscopy, ipsilateral tonsillectomy and
curettage of the nasopharynx and random biopsy from
the base of the tongue we found a primary tumor in 22/84
patients. In 1 patient with a nasopharyngeal carcinoma a
surgeon could not find suspicious place, but the nasopha-
ryngeal cancer was later confirmed with the help of the
PET-CT. The biopsy guided with the result of the PET-CT,
was also done in a patient with carcinoma on the base of
the tongue, because the primary tumor was not identi-
fied during the panendoscopy. Out of 22 patients in
which the primary tumor was found during the panendo-
scopy, 8 of these had a PET-CT scan. In 7 patients the pri-
mary tumor was found during the panendoscopy. In 1 pa-
tient in whom the cancer of the tonsils was found on
serial sections, there was no pathological uptake on PET-
-CT scan in the tonsillar region.
In 10/22 we found a primary tumor in the tonsils, in
3/22 in the hypopharynx and in 3/22 in the supraglottic
region. In 1/22 the tumor was identified in the base of the
tongue, in 1/22 in the glossotonsilar sulcus, 1/22 in the
nasopharynx and in 1 patient on the lungs.
Remaining 62 patients had true unknown primary.
Out of these 62 patients we excluded 9 of them from the
research because of their general poor condition, which
did not allow for treatment with curative intent and so
their treatment was only symptomatic. In 4 patients we
have a follow up shorter than 2 years, and therefore they
were excluded from survival analysis.
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For survival analysis we included 49 patients. Mean
age at time of diagnosis was 61 years. Median follow-up
was 36 months. Minimum follow-up of the patients alive
at the end of the study was 24 months.
In 10/49 patients we identified a primary tumor dur-
ing the follow up. In 4/10 the primary tumor was discov-
ered outside the area of the head and neck. In 3 patients
the primary tumor was identified in the abdomen (gas-
tric cancer in 2/10 and urinary bladder tumor in 1/10)
and at 1 in the chest (lung cancer). In 6 patients the pri-
mary tumor was found in the head and neck region, in
four in the oropharynx and in two in the oral cavity. All of
the patients who had been diagnosed with a primary tu-
mor outside the head and neck region died soon after the
discovery of the tumor. Two of them died because of the
disease progress, one from septic shock and one because
of the complications after the surgery. Currently 3/10 pa-
tients with tumor in the head and neck are still alive.
Two have a tumor in orpharynx and one with a cancer of
the floor of the mouth.
In 39/96 patients we could not identify primary tumor
during the preoperative workup or during follow up and
were treated with a neck dissection and postoperative ir-
radiation.
Table 1 represents both groups of patients and their
current status (age, gender, smoking, alcohol). The two
groups are: »CPT«- with confirmed primary tumor and
»WPT« – without primary tumor
The 2-year overall survival for CPT group was 80.0%
(±12.6% standard error), the 2-year overall survival for
WPT group was 73.8% (±7.1% standard error) (Figure 1).
The difference between groups is not statistically signifi-
cant (log-rank test, p=0.75).
The 2-year disease-specific survival for CPT group
was 90.0% (±9.5% standard error), the 2-year disease-
-specific survival for WPT group was 81.6% (±6.3% stan-
dard error) (Figure 2). The difference between groups is
not statistically significant (log-rank test, p=0.28).
We analyzed the difference between the patients with
metastasis in the upper and lower regions of the neck:
The 2-year overall survival for high neck level lymph
node metastasis group (N=36) was 80.1% (±6.7% stan-
dard error), the 2-year overall survival for low neck level
lymph node group (N=13) was 61.5% (±13.5% standard
error) (Figure 3). The difference between groups is sta-
tistically significant (log-rank test, p=0.009).
The 2-year disease-specific survival for high neck
level lymph node metastasis group (N=36) was 85.6%
(±6.0% standard error), the 2-year overall survival for
low neck level lymph node group (N=13) was 74.1%
(±12.9% standard error) (Figure 4). The difference be-
tween groups is statistically significant (log-rank test,
p=0.02).
The survival rate for patients with extracapsular
spread compared to the patients without is not statisti-
cally significantly different (Figure 5). Figure 6 repre-
sents survival curves for different stages of the nodal dis-
ease. It is evident that patients with more advanced
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TABLE 1
TWO GROUPS OF PATIENTS AND THEIR STATUS
CPT group confirmed primary tumor WPT group without primary tumor
No of patients 10 39
Gender (F/M) 1F / 9M 10F / 29M
Age at diagnosis (mean±SD) 53.8 (±15.1) 63.1 (±10.8)
Smoking (Yes/No) 9Y / 1N 28Y / 11N
Alcohol (Yes/No) 8Y / 2N 25Y / 14N
Fig. 1. Overall survival: CPT- with confirmed primary tumor;
WPT – without primary tumor.
Fig. 2. Disease-specific survival: CPT- with confirmed primary
tumor; WPT – without primary tumor.
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nodal disease have lower survival than those with a sin-
gle node.
The 2-year disease-specific survival for N group (N=
41) was 81.7% (±6.2% standard error), the 2-year dis-
ease-specific survival for Nesc group (N=8) was 87.5%
(±11.7% standard error) (Figure 5). The difference be-
tween groups is not statistically significant (log-rank
test, p=0.83).
The 2-year disease-specific survival for N1 group (N=
13) was 90.9% (±8.7% standard error), for N2 group
(N=29) was 82.1% (±7.2% standard error), and for N3
group (N=7) was 71.4% (±17.1% standard error) (Figure
6). The difference between groups is not statistically sig-
nificant (log-rank test, p=0.10).
Discussion
Patients with CUP usually have advanced cancer, but
we cannot identify primary tumors. There are different
protocols for preoperative management of the carcinoma
of the primary tumor. Nowadays the most popular is
PET-CT. There are different opinions about accuracy of
these methods. Deron with co workers7 could not find
any primaries on his 18 patients; however Wong and
Saunders found 8 primaries in their 17 patients. In this
current research we identified 8 primaries in 28 patients.
Only in two patients out of 8 we couldn’t identify pri-
mary tumor during the panendoscopy: in a patient with
nasopharyngeal cancer and a patients with base of the
tongue carcinoma. Therefore only in these two patients
PET-CT had advantage over the panendoscopy. On the
other way PET-CT is successful method if it is combined
with panendoscopy. With PET-CT the detection rate of
the suspicious places that were sampled is higher com-
pared to the panendoscopy alone. Panendoscopy, com-
bined with ipsilateral tonsillectomy, nasopharynx curet-
tage and tongue base biopsy has helped to identify 22
primaries in 84 patients. Ten patents had tonsillar can-
cers. Most of them were found after serial sections of the
tonsil at histology. Some authors9,10 advocate both-sided
tonsillectomy. On the other hand there are authors11 who
avoid routine tonsillectomy, and they advocate only phys-
ical exam with meticulous palpation. They perform ton-
sillectomy only in patients with clinically abnormal ton-
sil. It is not plausible for a small, early tonsillar cancer to
metastasize into contralateral lymph nodes. We believe
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Fig. 3. Overall survival of all patients regarding to neck level
lymph node: h-high/l-low (No of cases).
Fig. 4. Disease-specific survival of all patients regarding to neck
level lymph node: h-high/l-low (No of cases).
Fig. 5. Disease-specific survival of all patients – N subgroups (No
of cases).
Fig. 6. Disease-specific survival of all patients – N subgroups (No
of cases).
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that bilateral tonsillectomy is not indicated in CUP pa-
tients. With bilateral tonsillectomy the chances for post-
-operative bleeding are increased, but it makes oropha-
rynx symmetrical, which could be an important factor for
follow up. The symmetry is greatest argument in favor
for bilateral tonsillectomy. In this series we didn’t iden-
tify cancer in contralateral tonsil before or during the
treatment as well as in the follow up period.
During the follow up we identified ten primaries.
Four patients had primaries outside of head and neck re-
gion. All four patients didn’t have PET-CT scan. For this
reason we do not know if this patents had small prima-
ries before neck dissections, however on abdominal ul-
trasound examinations and chest X ray we could not find
any suspicious places. In other 6/10 patients during the
follow up we identified primaries in head and neck re-
gion, despite the postoperative radiotherapy. Three of
these six patients had had PET-CT scan. In all six pa-
tients there was no increased uptake 18F-odeoxyglucose
during the diagnostic workup. All patients with con-
firmed primaries outside of head and neck died very
quickly after diagnosis. Patients with identified primary
in the head and neck have better survival rate compared
to patients where primary could not be identified.
Boscolo-Rizzo with co-workers13 treated 88 patients
with CUP. Survival rate of this patients was 50,9 % at two
years but only 25,3 % at five years. Our patients have
72% two years survival and 35% five years survival. Dis-
ease specific survival is much better and for two years is
80 and 40% for five years. This survival is within the
range reported in the literature 35-66%14–16.
The standard therapy for CUP patients is comprehen-
sive neck dissection and postoperative radiotherapy of
the neck and upper aerodigestive tract17,18. Most our pa-
tients treated with curative intent had this therapeutical
protocol, small number had also concomitant chemother-
apy. Patients with metastases in higher neck level have
significantly better survival rate than patients with low-
er neck metastases. This is also reported in the literatu-
re2,19,20. But we have totally different results in patients
with extracapsular spread. Our patients with extrasca-
pular spread had better survival. Possible reason is a
small number of the patients int this group (three pa-
tients). Patients with smaller metastasis have better two
and five years survival than patients with more advanced
disease, which also corresponds to the data reported in
literature19–21.
Conclusion
Panendoscopy with ipsilateral tonsillectomy is the op-
timal method for identification of the primaries in the
head and neck in patients with CUP. PET-CT can be use-
ful only in combination with panendoscopy and it might
be helpful in identification of the primary outside of the
head and neck. We cannot draw any conclusions since the
number of the patients with PET-CT scan is too small.
Patients with primaries identified outside head and neck
region have worse prognosis and their survival rate is
lower. Our therapy protocol with comprehensive neck
dissection and post-operative radiotherapy yield compa-
rable results to that from the literature.
Two year survival rate is encouraging. Patients in
whom we discover the primary during the therapy and
have their primary in the head and neck and those who
have metastases in higher neck regions have a better sur-
vival rates. Because of the small number of patients a
multinstitutional prospective study would be needed to
evaluate the value of the PET-CTmethods of treatment.
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METASTAZE NEPOZNATOG PRIMARNOG CARCINOMA NA VRATU
S A @ E T A K
Cilj istra`ivanja je bio utvrditi pre`ivljavanje bolesnika sa metastazama vrata nepoznatog planocelularnog karci-
noma u ovisnosti o pro{irenosti metastatskog procesa i mogu}eg kasnijeg otkrivanja primarnog tumora. Opredjeliti
vrijednost PET-CT pretrage u tra`enju nepoznatog primarnog tumora. Napravljena je retrospektivna studija 97 bo-
lesnika sa metastazama vrata nepoznatog planocelularnog karcinoma, koji su bili primljeni na lije~enje na Odjel za
Otorinolaringologiju i maksilofacijalnu kirurgiju Uniiverzitetskog klin~kog centra Maribor u razdoblju od 1.1.1997 do
1.9.2009. Kod svih bolesnika napravljena je panendoskopija, a bolesnici koji su lije~eni u kasnijem periodu imaju i
pretragu sa PET-CT. Svi operabilni bolesnici bili su operirani i poslije operacije zra~eni. Po zavr{etku terapije u redov-
nom vremenskim razmacima kontrolirani su na Otorinolaringolo{kom odjelu UKC Maribor. Kod 48 bolesnika primarni
tumor bio je prona|en u toku pripreme za operativno lije~enje. Kod 13 bolesnika primarni tumor bio je prona|en sa
PET-CT pretragom, ali samo kod jednog od njih tumor nije bio prona|en drugim pretragama. Kod 39 bolesnika nismo
prona{li primarni tumor, a kod deset bolesnika primarni tumor prona{li smo u kasnijem periodu. Dvogodi{nje pro`iv-
ljavanje je kod bolesnika sa prona|enim primarnim tumorom 80,0%, a kod bolesnika bez prona|enog tumora 73,8%.
Specifi~no dvogodi{nje pre`ivljavanje je kod bolesnika sa prona|enim tumorom 90,0%, a kod bolesnika bez prona|enog
primarnog tumora 81,6%. Dvo godi{nje cjelokupno pro`ivljavanje bolesnika sa metstazama visoko na vratu (N= 36%)
iznosi 80,1%, a kod bolesnika sa metastazama nisko na vratu (N=13) iznosi 61,5%. Pretraga sa PET-CT u tra`enju
nepoznatog primarnog tumora nije se pokazala kao posebno korisna. Bolesnici sa metastazama visoko na vratu imaju
statisti~ki zna~ajno bolje pre`ivljavanje od bolesnika sa metastazama nisko na vratu.
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